Practice Guidelines in Oncology - Gastric Cancer

®
Practice Guidelines
NCCN in Oncology – v.1.2007
of adenocarcinoma of the gastric cardia (AGC) - report on 370
patients. Int J Radiat Oncol Biol Phys 1998;42:929-934.
53. Pyrhonen S, Kuitunen T, Nyandoto P, et al. Randomised
comparison of fluorouracil, epidoxorubicin and methotrexate
(FEMTX) plus supportive care with supportive care alone in patients
with non-resectable gastric cancer. Br J Cancer 1995;71:587-591.
54. Murad AM, Santiago FF, Petroianu A, et al. Modified therapy with
5-fluorouracil, doxorubicin, and methotrexate in advanced gastric
cancer. Cancer 1993;72:37-41.
55. Glimelius B, Hoffmann K, Haglund U, et al. Initial or delayed
chemotherapy with best supportive care in advanced gastric cancer.
Ann Oncol 1994;5:189-190.
56. Scheithauer W, Komek G, Zeh B, et al. Palliative chemotherapy
versus supportive care in patients with metastatic gastric cancer: A
randomized trial (abstract). Proceedings of the Second International
Conference on Biology, Prevention, and Treatment of GI
Malignancy. Koln, Germany, 1995:68.
57. Kelsen DP, Magill G, Cheng E, et al. Phase II trial of etoposide
(VP-16) in the treatment of upper gastrointestinal malignancies
(abstract). Proc Am Soc Clin Oncol 1982;1:96.
58. Lacave AJ, Izarzugaza I, Anton Aparicio LM, et al. Phase II
clinical trial of cis-dichlorodiammineplatinum in gastric cancer. Am J
Clin Oncol 1983;6:35-38.
59. Macdonald JS, Philip SS, Woolley PV, et al. 5-Fluorouracil,
doxorubicin and mitomycin (FAM) combination chemotherapy for
advanced gastric cancer. Ann Intern Med 1980;93:533-536.
Gastric Cancer
Manuscript
update in
progress
Version 1.2007, 03/09/07 © 2007 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.
Guidelines Index
Gastric Table of Contents
Staging, MS, References
60. Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of
three chemotherapeutic regimens in the treatment of advanced
pancreatic and gastric carcinoma: Fluorouracil versus fluorouracil
and doxorubicin versus fluorouracil, doxorubicin, and mitomycin.
JAMA 1985;253:2061-2067.
61. Wils JA, Klein HO, Wagener DJ, et al. FAMTX (5-FU, Adriamycin
and methotrexate): A step ahead in the treatment of advanced
gastric cancer: A trial of the European Organization for Research
and Treatment of Cancer of the Gastrointestinal Tract Cooperative
Group. J Clin Oncol 1991;9:827-831.
62. Webb A, Cunningham D, Scarffe JH, et al. Randomized trial
comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil,
doxorubicin, and methotrexate in advanced esophagogastric cancer.
J Clin Oncol 1997;15:261-267.
63. Wilke H, Wils J, Rougier P, et al. Preliminary analysis of a
randomized phase III trial of FAMTX versus ELF versus cisplatin/5-
FU in advanced gastric cancer (abstract). Proc Am Soc Clin Oncol
1995;14:206.
64. Einzig AI, Lipsitz S, Wiernik PH, et al. Phase II trial of Taxol in
patients with adenocarcinoma of the upper gastrointestinal tract:
The Eastern Cooperative Oncology Group (ECOG) results. Invest
New Drugs 1995;13:223-227.
65. Ohtsu A, Boku N, Tamura F, et al. An early phase II study of a 3hour
infusion of paclitaxel for advanced gastric cancer. Am J Clin
Oncol 1998;21:416-419.
66. Ajani JA, Fairweather J, Dumas P, et al. Phase II study of Taxol
in patients with gastric carcinoma. Cancer J Sci Am 1998;4:269-274.
REF-4